Amyloid-p (AP) peptide accumulation and aggregation are initiating events in the pathogenesis of Alzheimer's disease (AD). AB aggregation is concentration-dependent and can result from its overproduction, inefficient clearance, or both. LRP1 is a multifunctional lipoprotein receptor that modulates both AB production and clearance. While the fast endocytosis of LRP1 modulates the endocytosis and processing of amyloid precursor protein (APP) to influence AB production, the endocytic functions of both LRP1 and cell surface heparan sulfate proteoglycan (HSPG) facilitate cellular uptake and clearance of Ap. A major goal of this project is to examine the in vivo roles of LRP1 and HSPG in brain AP production and clearance in mice with altered gene expression by viral mediated or genetic approaches. Our recent collaborative work with the groups of David Holtzman and John Cirrito has also showed that synaptic activity regulates APP processing to AB, and that this regulation requires the endocytosis of APP. In addition to presynaptic mechanisms, AP producfion can also be regulated by a postsynaptic mechanism that involves NMDARs, which interact with LRP1. Therefore, we plan to determine whether LRP1/HSPGmediated Ap production or clearance is regulated by synaptic activity. Our overall hypothesis is that LRP1 and HSPG play critical roles in synaptic-dependent regulation of both AB production and clearance, and that dysregulation of these pathways leads to AP accumulation and aggregation in AD brains. To test our hypothesis, we will collaborate with Drs. David Holtzman and John Cirrito, who have extensive experience in modulating synaptic activity and measuring AB metabolism in vivo, to pursue three specific aims.
In Aim 1, we will dissect the role of LRP1 in synaptic-dependent AB generation in vivo.
In Aim 2, we will dissect the role of LRP1 and HSPG in synaptic-dependent AB clearance in vivo.
In Aim 3, we will examine the specific roles of LRPI and HSPG in neurons and astrocytes in AB metabolism and amyloid pathology in vivo using conditional knockout mice. Together, these studies should allow us to dissect the molecular mechanisms underlying synaptic regulation of brain AP metabolism and may define novel targets for AD therapy.

Public Health Relevance

AD is the leading cause of dementia in elderly. Mounting evidence indicates that AB accumulation and aggregation in the brain are central and early events in AD pathogenesis. The major goal of our project is to dissect molecular pathways that mediate AB production and clearance, and examine how these AP metabolic events are regulated by brain synaptic activity. Our studies should define AB metabolic pathways at the molecular and synaptic levels and should identify novel diagnostic and therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
1P01NS074969-01A1
Application #
8331631
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2013-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$263,985
Indirect Cost
$13,000
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Liao, Fan; Zhang, Tony J; Mahan, Thomas E et al. (2015) Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-? in an APP transgenic mouse model. Brain Behav Immun 47:163-71
Lim, Miranda M; Gerstner, Jason R; Holtzman, David M (2014) The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag 4:351-62
Shinohara, Mitsuru; Fujioka, Shinsuke; Murray, Melissa E et al. (2014) Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain 137:1533-49
Medway, Christopher W; Abdul-Hay, Samer; Mims, Tynickwa et al. (2014) ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener 9:11
Tai, Leon M; Mehra, Shipra; Shete, Varsha et al. (2014) Soluble apoE/A? complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 9:2
Liu, Chia-Chen; Tsai, Chih-Wei; Deak, Ferenc et al. (2014) Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron 84:63-77
Zhao, Jing; Fu, Yuan; Liu, Chia-Chen et al. (2014) Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem 289:11282-92
Martínez-Morillo, Eduardo; Hansson, Oskar; Atagi, Yuka et al. (2014) Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol 127:633-43
Kanekiyo, Takahisa; Xu, Huaxi; Bu, Guojun (2014) ApoE and A? in Alzheimer's disease: accidental encounters or partners? Neuron 81:740-54
Ju, Yo-El S; Lucey, Brendan P; Holtzman, David M (2014) Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol 10:115-9

Showing the most recent 10 out of 15 publications